

Technology Appraisal Committee A Interests Register

Topic: Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

Publication Date: 10th September 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Steve Edwards	TAC Committee Member	Professional	Steve will not be attending ID6415 as he is a member of the EAG for that topic	20/05/2025	It was agreed that Steve's declaration would prevent him from participating in discussions on this appraisal.
James Fotheringham	TAC Committee Member	Indirect – Financial	Performed systematic reviews for AZ on the subject of hypertension.	21/05/2025	It was agreed that James' declaration would not prevent him from participating in discussions on this appraisal.
Zoe Philips	TAC Committee Member	Direct - Financial	Zoe has received income (via salary) by working as a consultant for two of the comparator companies (BMS, Merck, Sharpe and Dohme) but in a different indication.	22/05/2025	It was agreed that Zoe's declaration would not prevent her from participating in discussions on this appraisal.
Patrick de Barr	TAC Committee Member	Direct – Financial Interests	Patrick is currently employed by GSK and so therefore should not participate in this appraisal	22/05/2025	It was agreed that Patrick's declaration would prevent him from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					discussions on this appraisal.
Dominic Pivonka	TAC Committee Member	Indirect - Financial	Dominic's employer (AbbVie) has a treatment being evaluated for endometrial cancer in phase 1	26/05/2025	It was agreed that Dominic's declaration would not prevent him from participating in discussions on this appraisal.
Hugo Pedder	TAC Committee Member	Indirect - Financial	Hugo has received payment for work on behalf of Baxter Healthcare in the last 12 months for a technology and indication unrelated to this. He has received payment for methodological training on behalf of MSD in the last 12 months (no specific technology/indication)	03/06/2025	It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal.
Dr John McGrane	Clinical Expert	Direct – financial	GSK – Advisory boards, Speaking fees, travel support MSD - Advisory boards, Speaking fees Eisai- Advisory boards, Speaking fees	01/07/2025	It was agreed that Dr McGrane's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Astra Zeneca – Advisory Board</p> <p>BMS - Advisory boards, Speaking fees, travel support</p> <p>Merck- Advisory boards, Speaking fees</p> <p>Astellas - Speaking fees</p> <p>Ipsen - Advisory boards, Speaking fees, travel support</p> <p>Pfizer - Advisory boards, Speaking fees</p> <p>Roche – Advisory board</p> <p>Director – MySunrise cancer support app</p>		
Dr Andrew Clamp	Clinical Expert	Direct financial	<p>GSK-Advisory board participation to discuss results of trials of dostarlimab in endometrial cancer. £1620</p>	01/07/2025	It was agreed that Dr Clamp's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			GSK- Membership of organising committee and speaker at endometrial cancer summit meeting. £2160		